# Sharay

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sharay

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.sharay.com.cn
- Total disclosed funding: $14M
- Latest round: Series B (Jul 20, 2023)
- Investors on record: 3

## About

Founded in 2018 and based in Chengdu, China, Sharay is a biotech company that focuses on the research and development of core raw materials for in vitro diagnostic reagents. In 2020, the company obtained 29 NMPA registration certificates. In July 2023, the firm raised approximately CNY 100 million in series B funding co-led by new investors 3E Bioventures Capital and Bio Venture. It has a research and development center in Suzhou and industrial platforms in Sichuan and Hunan.

The company's main product is a fully automatic chemiluminescence analyzer. It also offers autoimmune testing, allergen testing, cytokine testing, and thrombosis testing.

## Funding rounds

- Series B, Jul 20, 2023, $14M — YuanBio Venture, 3E Bioventures Capital
- Series A, Jan 5, 2022 — BridgeOne Capital

## Investors

- BridgeOne Capital (https://capitalatlas.ai/funds/bridgeone-capital) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series B
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series B